GB5005 / Genechem 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   3 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GB5005 / Genechem
ChiCTR-OIN-15007668: Open-label, uncontrolled, single-arm pilot study to evaluate cellular immunotherapy using CD19-targeted chimeric antigen receptor engineered T cells in patients with relapsed or refractory CD19+ B cell leukemia

Not yet recruiting
1
30
 
anti-CD19-CAR-T cells
Shanghai Changhai Hospital，The Second Military Medical University; Shanghai GeneChem Co., Ltd., Shanghai GeneChem Co.,Ltd.
relapsed or refractory CD19+ B cell leukemia
 
 
ChiCTR2000035631: A clinical compartive study of autologous CD19 CAR-T cells alone and its sequential ASCT in the treatment of relapsed and refractory B-cell lymphoma ------Multi-center, randomized, open clinical controlled study

Not yet recruiting
N/A
60
 
CART treatment sequential ASCART treatment of sequential ASCT ;CART cell alone treatment
Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Genechem Co., Ltd
CD19 positive relapsed/refractory B-cell lymphoma
 
 

Download Options